Span Divergent Fair Value
Span Divergent (SDL) average fair value is ₹35.35 across 2 valuation models — Price-to-Sales Valuation, Discounted Cash Flow (DCF), vs a current market price of ₹36.67 (-3.59%), fair value range ₹9.59–₹61.12. See SDL P/B ratio history to compare market price against book value per share.
Fair Value Analysis Export
SDL Fair Value vs Current Price — Valuation Summary
SDL average fair value, fair value range, price gap and valuation status across 2 models: Price-to-Sales Valuation, Discounted Cash Flow (DCF). Examine SDL Q4 results for recent quarterly revenue, profit and EPS trends.
Price-to-Sales Valuation
Discounted Cash Flow (DCF)
SDL Fair Value Analysis — Data Sources & Coverage
Span Divergent financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit Span Divergent share price screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
SDL vs Healthcare Sector Peers — P/E, P/B & Market Cap
Span Divergent P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Aurobindo Pharma | AUROPHARMA | 25.16 | 2.5 | ₹87,806 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.